• Reuters

  • SHARE

Eisai Co. on Friday said it still plans to seek an accelerated U.S. approval pathway for its experimental Alzheimer's drug even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.

On Thursday, after a monthslong review and a pressure campaign from patient advocacy groups, the Centers for Medicare and Medicaid Services (CMS) said it would only pay for Biogen Inc.'s Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless they have demonstrated clear evidence of patient benefit.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)